F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review by Milly A Schröer-Günther et al.
Schröer-Günther et al. Systematic Reviews 2012, 1:62
http://www.systematicreviewsjournal.com/content/1/1/62SYSTEMATIC REVIEW UPDATE Open AccessF-18-fluoro-2-deoxyglucose positron emission
tomography (PET) and PET/computed
tomography imaging in primary staging of
patients with malignant melanoma: a systematic
review
Milly A Schröer-Günther1*, Robert F Wolff2, Marie E Westwood2, Fülöp J Scheibler1, Christoph Schürmann1,
Brigitta G Baumert4, Stefan Sauerland1 and Jos Kleijnen2,3Abstract
Purpose: The aim of this systematic review was to systematically assess the potential patient-relevant benefit
(primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and
PET/computed tomography (CT) in primary staging of malignant melanoma. This systematic review updates the
previous evidence for PET(/CT) in malignant melanoma.
Materials and methods: For the first aim, randomized controlled trials (RCTs) investigating patient-relevant
outcomes and comparing PET and PET(/CT) with each other or with conventional imaging were considered. For
the secondary aim, a review of reviews was conducted, which was amended by an update search for primary
studies. MEDLINE, EMBASE and four databases of the Cochrane Library were searched. The risk of bias was assessed
using a modified QUADAS tool.
Results: No RCTs investigating the patient-relevant benefit of PET(/CT) and no prognostic accuracy studies were
found. Seventeen diagnostic accuracy studies of varying quality were identified. For patients with American Joint
Committee on Cancer (AJCC) stages I and II, sensitivity mostly ranged from 0 to 67%. Specificity ranged from 77 to
100%. For AJCC stages III and IV, sensitivity ranged from 68 to 87% and specificity from 92 to 98%.
Conclusion: There is currently no evidence of a patient-relevant benefit of PET(/CT) in the primary staging of
malignant melanoma. RCTs investigating patient-relevant outcomes are therefore required. The diagnostic accuracy
of PET(/CT) appears to increase with higher AJCC stages.
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Malignant melanoma accounts for about 5% of all skin
cancers [1]. Depending mainly on the initial stage of dis-
ease, survival after diagnosis can range from only a few
months to many years [2]. Once distant metastases have
been diagnosed, median survival in untreated patients
amounts to 6 to 9 months [3]. Accurate primary staging
is therefore essential for developing an appropriate treat-
ment strategy. Conventional techniques for staging in-
clude computed tomography (CT), magnetic resonance
imaging, skeletal scintigraphy, and conventional X-ray [4].
Positron emission tomography (PET) is a nuclear-
medical imaging method that provides information on
the function and metabolism of tissue (metabolic
imaging) and is used as a stand-alone procedure (PET)
or in combination with CT (PET/CT). A number of
international societies have concluded that PET(/CT)
is useful for detection of metastasis in patients with
American Joint Committee on Cancer (AJCC) stages
III and IV [2-5]. A current UK guideline states that
there is good evidence against the use of PET(/CT) for
detection of metastasis in patients with AJCC stages I
and II [6].
This systematic review formed part of a health tech-
nology assessment report that will be used to guide
national policy on the reimbursement of PET(/CT)
in Germany.
The full protocol and report are available on the web-
site of the responsible health technology assessment
agency [7,8], whose tasks and methodological approach
are described in its paper on general methods [7,8]. The
main aim of this systematic review was to assess the po-
tential patient-relevant benefit of PET(/CT) in primary
staging of malignant melanoma. Our secondary aim was
to assess the diagnostic and prognostic accuracy of PET
(/CT) in the same indication (detection of regional
lymph node metastases and/or diagnostic accuracy for
detection of distant metastases).Materials and methods
Search strategy and study selection
For our primary aim (that is, assessment of patient-
relevant benefit) we searched for relevant randomized
controlled trials (RCTs) investigating at least one prede-
fined patient-relevant outcome (see below). In this con-
text, the term ‘patient-relevant’ refers to how a patient
feels, functions or survives. If insufficient evidence was
available to answer the primary question, an assessment
of the diagnostic and prognostic accuracy of PET(/CT)
was performed (secondary aim). For this purpose, a re-
view of reviews was conducted, and where appropriate,
supplemented with additional recent primary studies
identified by our own update search.Primary studies were searched for in MEDLINE (1948
to January 2011) and EMBASE (1980 to January 2011)
via Ovid, and in the Cochrane Central Register of Con-
trolled Trials. The Cochrane Database of Systematic
Reviews, the Database of Abstracts of Reviews of Effects,
and the Health Technology Assessment Database were
screened to identify systematic reviews. In addition,
reference lists of retrieved articles and conference pro-
ceedings were searched by hand. Databases of guideline
developers were also searched to identify further system-
atic reviews. Finally, web-based clinical trial registries
and trial results databases were screened. The search
strategy included bibliographic index terms on melan-
oma and PET. The full search strategy, which was devel-
oped by one information specialist and checked by
another, has been described elsewhere [7,8]. Two
reviewers independently screened titles and abstracts of
the retrieved citations to identify potentially eligible pri-
mary and secondary publications. The full texts of these
articles were obtained and independently evaluated by
the same two reviewers applying the full set of inclusion
and exclusion criteria. Disagreements were resolved by
consensus.
Eligibility criteria
For our primary aim, RCTs with the following character-
istics were included. First, the RCT investigated patients
with malignant melanoma. Second, the trial evaluated at
least one of the following predefined patient-relevant
outcomes: health-related quality of life, melanoma-
related mortality, all-cause mortality, and other adverse
events. Third, in the RCT either PET and/or PET/CT
were compared with each other or with another diag-
nostic test (for example, CT), or PET or PET/CT was
used to identify patients and assign them to different
treatment regimens based on the test result (for ex-
ample, enrichment design). Finally, there was a full-text
document available (no language restrictions).
For the secondary aim, systematic reviews identified in
the literature search were evaluated using Oxman and
Guyatt’s quality tool [9,10]. Eligible systematic reviews
had to achieve five or more of seven possible points in
order to be included in our review. In addition, we con-
ducted an update search for primary studies published
up to January 2011 to cover the period not considered
by the systematic reviews.
With regard to diagnostic and prognostic accuracy, we
extracted and analyzed data from primary studies (iden-
tified either by the published high-quality systematic
reviews or by our literature search) if the following cri-
teria were fulfilled:
prospective design; patient-based analysis; index test
(PET or PET/CT); valid reference standard (histopath-
ology, clinical follow-up >6 months, or a combination of
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example, for M-staging), we also accepted studies that
only applied clinical-radiologic follow-up; number of
patients (at least 10); sufficient data for calculation of
2×2 tables; and full-text document available.
Where the number of studies that investigated a direct
comparison of PET or PET/CT with other diagnostic
procedures was insufficient, we also included verification
of only positive testers design studies and discordance
studies. In the verification of only positive testers design,
the reference standard is applied only to those patients
in whom a suspicious lesion was found by one or both
of the index tests. In the discordance design, the refer-
ence standard is applied only to those patients in whom
one test, but not both tests, was positive (that is, where
there is a discordant result).
Data extraction
The individual steps of the data extraction and risk-of-
bias assessment procedures were conducted by one re-
viewer and checked by another; disagreements were
resolved by consensus. As no RCTs and prognostic ac-
curacy studies were identified, no further details of the
planned data extraction and risk-of-bias assessment are
provided here.
Using standardized tables, information was extracted
from each included diagnostic study on: baseline charac-
teristics of the study participants; characteristics of the
index test and reference standard; data for constructing
2×2 contingency tables of diagnostic and prognostic ac-
curacy (that is, numbers of true-positive, false-negative,
false-positive and true-negative test results); reported
sensitivities and specificities of PET(/CT); and risk-of-
bias items (see below).
Assessment of risk of bias
The risk of bias in diagnostic accuracy studies identified
in the update search was evaluated using a modified ver-
sion of QUADAS, an evidence-based tool recommended
for assessing the methodological quality of test accuracy
studies [11]. We modified this tool because, in our opin-
ion, some QUADAS items referred more to external val-
idity than to internal validity. Since our review was
undertaken, a revised version of QUADAS (QUADAS-2)
has been released [12]. QUADAS-2 more closely resem-
bles the approach and structure of the Cochrane risk-of-
bias tool. Furthermore, it aims to produce an assessment
of the risk of bias by methodological domain (participant
selection, index test, reference standard, and flow of par-
ticipants through the study), rather than the more gen-
eral overall risk of bias.
The following criteria were assessed: item 1, applica-
tion of a reference standard likely to correctly classify
the target condition; item 2, observance of anappropriate time period between application of the refer-
ence standard and the index test; item 3, independence
of the index test from the reference standard; items 4 to
6, avoidance of partial verification bias, differential verifi-
cation bias, and incorporation bias; item 7, interpret-
ation of the reference standard without knowledge of
the results of the index text; item 8, performance of an
intention-to-diagnose analysis; item 9, avoidance of se-
lective reporting; and item 10, no identification of other
aspects contributing to a risk of bias.
The QUADAS tool does not recommend the use of
algorithms to derive overall ratings of study quality.
However, the revised version of the QUADAS tool
(QUADAS-2) allows for an overall rating of ‘low risk of
bias, where all criteria are met’ [12]. For this evaluation
we developed topic-specific scoring guidance. In particu-
lar, we modified the requirement for all criteria to be
met, to allow for the fact it was not possible for studies
to meet item 5 (differential verification bias). The studies
were then categorized as follows. If one of the items was
evaluated with ‘no’ (except item 5), the study was rated
as having a high risk of bias. If at least two of the items
were rated as ‘unclear’, the study was also rated as having
a high risk of bias – items 7, 8 and 10 were exceptions;
here at least two items (plus an additional one from
items 1 to 6 or 9) had to be rated as ‘unclear’ in order to
conclude a high risk of bias.
The risk of bias in the diagnostic accuracy studies
identified by the systematic reviews was classified
according to the ratings given in the respective reviews.
Data analysis
Sensitivity and specificity were calculated from contin-
gency tables as reported in or derived from the studies.
The 95% confidence intervals were computed using the
Clopper and Pearson method [13]. Owing to great clin-
ical heterogeneity, bivariate analyses did not seem appro-
priate. The meta-analyses of the diagnostic accuracy
values from the included studies are presented in forest
plots according to analyses of all patients with AJCC
stages I to IV and of two subgroups (AJCC stages I and
II, and AJCC stages III and IV).Results
Literature search
The search for primary studies (that is, the search for
RCTs investigating the patient-relevant benefit of PET
(/CT) as well as the update search for diagnostic and
prognostic accuracy studies) retrieved 9,824 references.
However, no relevant RCT on the primary aim of our re-
view was identified (Figure 1).
Concerning the secondary aim, four high-quality po-
tentially relevant systematic reviews on the diagnostic
Figure 1 Flow chart of study.
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retrieved from 1,650 citations. After extraction of the
study information, the systematic reviews by Mijnhout
and colleagues [16] and Xing and colleagues [17] were
excluded from our review. Additional studies investi-
gated by Mijnhout and colleagues and by Xing and
colleagues that were not already included through
Jiménez-Requena and colleagues [14] or Krug and col-
leagues [15] did not fulfill our inclusion criteria due to
retrospective study designs, due to the reporting of
solely nonpatient-based analyses, or because 2×2 tables
could not be reconstructed. However, both of the
excluded high-quality reviews are addressed in the dis-
cussion section of this paper. We did not find any dis-
cordance studies or studies using a verification of only
positive testers design.
Our review of reviews was ultimately based on primary
studies included in two systematic reviews [14,15].
Eleven primary studies included in these reviews met
our inclusion criteria.The searches conducted in the two included reviews
ended in March 2007. Our update search therefore cov-
ered the period from March 2007 to January 2011 and
identified six further relevant studies. In total we there-
fore included 17 primary studies on diagnostic accuracy
in our review. No relevant prognostic study was found.
Study characteristics
The characteristics of the 17 diagnostic accuracy studies
(1,155 patients) are presented in Additional file 1.
Twelve studies investigated PET and five studies investi-
gated PET/CT; the latter studies were exclusively iden-
tified by our update search. All included studies used
F-18-fluoro-2-deoxyglucose as a tracer.
The age of patients ranged from 18 to 89 years. The
mean percentage of males per study was 51.0% and the
mean number of participants was 68 (range 17 to 251).
The studies were published between 1998 and 2010.
Six studies included patients with primary tumors in
AJCC stages I and II [18-23]. Three studies analyzed
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stages II and III [24], patients with AJCC stages II to IV
[25], and patients with AJCC stages I to III [26]. For
three further studies, information on AJCC stages was
missing [27-29].Risk of bias
The risk of bias varied across studies. Both systematic
reviews used different assessment tools. Jiménez-
Requena and colleagues modified items from previous
systematic reviews on PET [30-33]. These items covered
seven dimensions: ‘description of study design, descrip-
tion of the study population, indications leading to F-18-
fluoro-2-deoxyglucose PET use, technical and image
interpretation issues, final confirmation, sensitivity and
specificity data, and change in management information’
[14]. A score >70% was defined as high quality (low risk
of bias); six of the 10 studies included in our review were
defined as having a low risk of bias by Jiménez-Requena
and colleagues [18-20,24-26].
Krug and colleagues assessed the risk of bias using the
QUADAS tool [11]. Detailed information was provided
on the potential sources of bias and the proportion of
affected studies. These sources were, among others: the
inclusion of an inappropriate range of patients, the in-
sufficient description of inclusion and exclusion criteria,
insufficient information on primary tumors, the lack of
an independent interpretation of the index test and
reference standard, and insufficient explanation of with-
drawals. However, only a QUADAS sum score was pro-
vided for individual studies, which does not discriminate
between what could be a wide variety of quality issues
(different sources of bias and reporting and applicability
issues) and in addition does not distinguish between in-
ternal and external validity. Furthermore, no categorization
of studies into those with a high risk and those with a
low risk of bias was performed. The QUADAS sum
score was developed by Krug and colleagues, which isTable 1 Risk-of-bias assessment of studies published after Ma
Study Item 1 Item 2 Item 3 Item 4 It
Maubec and colleagues [28] Yes Unclear Yes Yes N
Strobel and colleagues [36] No Unclear Yes Yes N
Singh and colleagues [23] Yes Unclear Yes Yes N
Bastiaannet and colleagues [35] Yes Unclear Yes Yes N
Veit-Haibach and colleagues [37] Yes Yes Yes Yes N
Aukema and colleagues [34] Unclear Unclear Yes Yes N
Item 1, reference standard likely to correctly classify the target condition appropriat
appropriate; item 3, interdependence of test appropriate; item 4, partial verification
reference standard results interpreted without knowledge of the results of the inde
selective reporting; item 10, no other aspects. Yes, low risk of bias; no, high risk of b
aPositron emission tomography (PET) studies had a differential verification bias bec
biopsy. Item 5 was not considered in the risk-of-bias assessment.not recommended by the authors of QUADAS. How-
ever, one study fulfilled all QUADAS criteria [20].
The seven studies included in both reviews were
rated similarly [18-20,22,24,26,27], independent of the
assessors. All studies except the study by Rinne and
colleagues [22] were classified as having a low risk of
bias.
Of the six studies published after March 2007 and
identified in the update search [23,28,34-37], two had a
high risk of bias [28,35]. The main weaknesses of these
two studies were: the time period between the reference
test and the index test was inappropriate or unclear
(Table 1, item 2), incorporation bias was evident (item
6), the results of the reference test were interpreted with
knowledge of the results of the index test or the corre-
sponding information was missing (item 7), or no
intention-to-diagnose analysis was performed (item 8).Analyses
Diagnostic accuracy
The results for diagnostic accuracy are displayed in
Table 2. We did not pool data in meta-analyses because
of differences in indications (N-staging or M-staging, or
a mix of both), reference standards and index tests. The
sensitivity of PET(/CT) of all included studies ranged
from 0 to 100%; specificity ranged from 18 to 100%.
Eleven analyses (nine studies) on the detection of regional
lymph node metastases (N-staging) were included. Seven
analyses were based on PET and four on PET/CT. They
demonstrated a sensitivity and specificity for PET(/CT) of
0% (specificity 80.6%) to 100% (specificity 77%) and 18%
(sensitivity 40%) to 100% (sensitivity 8 to 38%), respect-
ively [18,19,21,23,25-27,34,37]. Seven analyses were based
on PET and four on PET/CT.
Six analyses on the detection of distant metastases
(M-staging) were performed in five studies [24,25,29,35,37].
Five analyses were based on PET and one on PET/CT.
The sensitivity of PET(/CT) ranged from 33% (specificityrch 2007
em 5a Item 6 Item 7 Item 8 Item 9 Item 10 Risk of bias
o Yes Unclear Yes Yes Unclear Low
o No Unclear Unclear Yes Unclear High
o Yes No Unclear Yes Unclear High
o Yes Unclear Unclear Yes Unclear Low
o Unclear Yes No Yes Unclear High
o Unclear Unclear Yes Yes Unclear High
ely; item 2, time period between reference standard and index test
avoided; item 5, differential verification bias; item 6, incorporation bias; item 7,
x test; item 8, intention-to-diagnose analysis performed; item 9, Free from
ias; unclear, information for assessment of the item is missing.
ause PET nonresponders were only followed up, instead of undergoing a
Table 2 Results of included studies




Rinne and colleagues [22] N-staging and M-
staging
PET 4 0 11 37 100 (40 to 100) 77 (63 to 88)
Crippa and colleagues [27] N-staging PET 17 2 3 16 90 (66.9 to 98.7)b 84 (60.4 to 96.6)b
Eigtved and colleagues [24] M-staging PET 28 1 4 5 97 (82 to 100) 56 (21 to 86)
Klein and colleagues [21] N-staging PET 2 1 0 14 67 (9.4 to 99.2)b 100 (76.8 to 100)b
Acland and colleagues [18] N-staging PET 0a 14a 7a 29a 0 (0 to 23.2)b 80,6b (64.0 to 91.8)b
Belhocine and colleagues [19] N-staging PET 1a 5a 1a 14b 16.7b (0.4 to 64.1)b 93.3b (68.1 to 99.8)b
Reinhardt and colleagues [29] M-staging PET 23 2 1 41 92 (74.0 to 99.0)b 98 (87.4 to 99.9)b
Hafner and colleagues [25] M-staging PET 0 0 2 98 – 98 d (93.0 to 99.8)d
N-staging PET 2 24 0 74 8 (0.9 to 25.1)b 100 (95.1 to 100)b
Fink and colleagues [20] N-staging PET 1 7 0 40 13 (0 to 53) 100 (91 to 100)
Vereecken and colleagues
[26]
N-staging PET 4a 6a 27a 6a 40.0b (12.2 to 73.8)b 18.2b (7.0 to 35.5)b
Brady and colleagues [45] N-staging and M-
staging
PET 30 14 5 54 68 (52 to 81) 92 (81 to 97)
Maubec and colleagues [28] N-staging and M-
staging
PET/CT 1b 5b 5 14 17 (0.4b to 64) 74 (49 to 91)
Strobel and colleagues [36] N-staging and M-
staging
PET/CT 45 8 3 68 85 (72.4 to 93.3)b 96 (88.1 to 99.1)b
PET/CT and separate
CT
52 1 4 67 98 (89,9 to 100)b 94 (86.2 to 98.4)b
Singh and colleagues [23] N-staging PET/CT 2 12 2 36 14.3 (2.5 to 44) b 94.7 (81 to 99)
Bastiaannet and colleagues
[35]
M-staging PET 68 11 11 161 86.1b (76.5 to 92.8)b 93.6b (88.8 to 96.8)b
CT 61 17 11 162b 78.2b (67.4 to 86.8)b 93.6b (88.9 to 96.8)b
Veit-Haibach and colleagues
[37]
N-staging PET/CT 5b 8 0 43b 38.5 (14 to 68) 100 (92 to 100)
PET 5b 8 0 43b 38.5 (14 to 68) 100 (92 to 100)
CT 3b,
c
10 0 43b,c 23.1 (5 to 53) 100 (92 to 100)
M-staging PET/CT 5b 7 3 41b 41.7 (15 to 72) 93.2 (81 to 99)
PET 4b 8 4 40 b 33.3 (9 to 65) 90.9 (78 to 97)
CT 3b,
c
9 3 41b,c 25.0 (5 to 57) 93.2 (81 to 99)
Aukema and colleagues [34] N-staging PET/CT 26 4 1 39 86.7b (69.3 to 96.2)b 97.5b (86.8 to 99.9)b
CI, confidence interval; CT, computed tomography; FN, false-negative; FP, false-positive; PET, positron emission tomography; TN, true-negative; TP, true-positive;
aData were extracted from primary study.
bOur own calculation.
cThe combination of TP and TN is reported in Table 3 of the study publication. Our own calculation of these values was possible because of the additional
information provided in the publication.
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(sensitivity 97%) to 98% (sensitivity 92%) [24,25,29,35,37].
Four studies reported contingency tables for both indi-
cations (N-staging and M-staging) [20,22,28,36].
In two studies, differences in diagnostic accuracy be-
tween imaging procedures were tested for statistical sig-
nificance [35,37]. Veit-Haibach and colleagues analyzed
PET versus PET/CT and PET versus CT [37]. Sensitivity
was low for all technologies whereas specificity was high.
No statistically significant differences were detected be-
tween the technologies.
Analyses by Bastiaannet and colleagues showed that
PET and CT performed similarly regarding the detection
of liver, lung and abdominal metastases (P = 0.81, P = 0.16and P = 0.62, respectively, no estimates and confidence
intervals provided) [35].
Subgroup analysis
In patients with AJCC stages I and II, the sensitivity of
PET(/CT) ranged from 0% (specificity 81%) to 67% (spe-
cificity 100%) (Figure 2). In four studies of this subgroup,
the sensitivity of PET(/CT) ranged from 0% (specificity
81%) to 17% (specificity 93%), while in the other two
studies the sensitivity was 67% (specificity 100%) and
100% (specificity 100%). The specificity of PET(/CT) in
this subgroup ranged between 77% (sensitivity 100%)
and 100% (sensitivity 13 or 67%). Three studies investi-
gated AJCC stages III and IV; in this second subgroup,
Figure 2 Forest plots of diagnostic accuracy.
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92%) to 87% (specificity 98%) (specificity 92% (sensitivity
68%) to 98% (sensitivity 87%)).
In the third group, studies including patients in all
stages (AJCC stages I to IV) were compared. The sensi-
tivity of PET(/CT) ranged from 17% (specificity 74%) to
97% (specificity 56%) and specificity ranged from 18%
(sensitivity 40%) to 100% (sensitivity 38%).
Veit-Haibach and colleagues analyzed M-staging and
N-staging for PET(/CT) [37]. The 2×2 tables for PET
(/CT) for N-staging showed identical results. Only three
2×2 tables are therefore presented in Figure 2. Sensitivity
ranged from 17% (specificity 74%) to 97% (specificity
56%). Sensitivity could not be calculated for Hafner and
colleagues as no true-positive and false-negative cases
were detected by PET [25]. In six studies, specificity ran-
ged from 56% (sensitivity 97%) to 100% (sensitivity 38%),
except for Vereecken and colleagues [26], with a specifi-
city of 18% (sensitivity 40%).
Discussion
Despite a comprehensive search, no RCT investigating
the potential patient-relevant benefit of PET(/CT) in pri-
mary staging of malignant melanoma was identified.
Only diagnostic accuracy studies were found, which
were retrieved from two previous systematic reviews and
from an update search.
For N-staging and M-staging, the results of the indi-
vidual studies varied widely in their estimates of sensitiv-
ity and specificity. Potential sources of heterogeneityincluded differences in the risk of bias, in the reference
tests and index tests applied and in the spectrum of
patients investigated. Stratification by disease stage indi-
cated that the diagnostic accuracy of PET(/CT) varied
with AJCC stage. PET(/CT) performed better in patients
with AJCC stages III and IV than in those with lower
AJCC stages. However, higher sensitivity and specificity
of PET(/CT) in AJCC stages III and IV do not necessar-
ily imply that there is a patient-relevant benefit of PET
(/CT) in this subgroup. The aim of diagnostic accuracy
studies is only to explain how well a new diagnostic test
agrees with the reference standard. One cannot draw
conclusions from diagnostic accuracy studies as to how
variations in the test strategy may ultimately affect a
patient’s outcomes. Likewise, robust conclusions cannot
be drawn from nonrandomized studies as the potential
risk of bias is higher than in randomized ones [38-40].
Moreover, diagnostic accuracy studies are unable to an-
swer effectiveness questions. Owing to the lack of direct
comparisons in our review, there is no evidence that the
diagnostic accuracy of PET(/CT) is better than conven-
tional imaging.
Our search identified four high-quality systematic
reviews investigating diagnostic accuracy [14-17], of
which two were included in the actual assessment.
All four reviews conducted meta-analyses: Xing and
colleagues [17] and Jiménez-Requena and colleagues
[14] presented separate analyses for N-staging and M-
staging, whereas Krug and colleagues [15] and Mijnhout
and colleagues [16] presented combined analyses.
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refrained from pooling data due to heterogeneity. In
contrast, we refrained from conducting any meta-
analyses at all because, in our view, the studies were too
heterogeneous; for example, concerning patient charac-
teristics (AJCC stage, age, primary cancer site, and so
forth) or the use of different index or reference tests (for
example, newer studies applied PET/CT whereas older
ones applied PET).
For information purposes, we present the results of
the meta-analyses or ranges for individual studies in
Table 3. However, we emphasize that the results lack
comparability due to various factors.
For example, all four of the other reviews included
both prospective and retrospective studies whereas we
only included prospective ones. The quality of studies
with a retrospective design is limited due to factors such
as spectrum bias, attrition bias, unclear blinding, the
often lacking standardised implementation of the index
and reference test, and especially the lack of the pro-
spective definition of cutoff points [41]. For future
reviews we would suggest performing a comparison ofTable 3 Results of meta-analyses on diagnostic accuracy
N-staging
Our review PET (analyzed by patients)
PET/CT (analyzed by patients)
Xing and colleagues [17] PET (analyzed by patients and lesion
PET/CT (analyzed by patients and les
Jimenéz-Requena and colleagues [14] PET (analyzed by lymph nodes)b
PET (analyzed by patients)
PET (analyzed by areas)b
M-staging
Our review PET (analyzed by patients)
PET/CT (analyzed by patients)
Xing and colleagues [17] PET (analyzed by patients and lesion
PET/CT (analyzed by patients and les
Jimenéz-Requena and colleagues [14] PET (analyzed by patients)
PET (analyzed by lesions)b
PET (analyzed by areas)b
PET (analyzed by Scans)b
N-staging and M-staging
Our review PET(analyzed by patients)
PET/CT (analyzed by patients)
Krug and colleagues [15] PET (analyzed by patients, lesions an
Mijnhout and colleagues [16] PET (analyzed by patients, lesions an
CT, computed tomography; PET, positron emission tomography. aPooled estimate w
of median with credible intervals; Jiménez-Requena and colleagues, specification of
nonpatient-based analyses are not relevant for our review. cAuthors reported that q
only one study. eSince the data were too heterogeneous, a quantitative synthesis o
our systematic review is highlighted in bold font face.results between study types (prospective vs. retrospect-
ive); for example, in the form of sensitivity analyses.
A further reason for the noncomparability of results is
the fact that the analyses in the other reviews were
largely not exclusively patient-based, but lesion-based.
From a statistical point of view, a lesion-based analysis
overestimates the precision of results. In our opinion, if
not properly accounted for, this type of analysis also
ignores the fact that observations on lesions of a given
patient are not independent, which may lead to bias.
As already recommended in the literature [42], we
suggest that studies on PET imaging report a patient-
based analysis as the primary analysis; other types of
analyses should always be adjusted for patients or should
only be presented as supplementary information.
Furthermore, when examining the diagnostic accuracy
of PET in N-staging, we could not reproduce some of
the results presented by Xing and colleagues [17], who,
for example, reported a specificity of 100% for the stud-
ies by Kokoska and colleagues and Longo and colleagues
[43,44]. However, specificity in these studies was not
reported and could not be calculated; therefore, despiteSensitivity (%) (95% CI)a Specificity (%)(95% CI)a
0 to 90e 18.2 to 100e
14 to 87e 95 to 100e
s; mixed)b 30 (12 to 55) 96 (87 to 99)
ions; mixed)b 11 (1 to 50) 97 (97 to 100)
–c 99 (97 to 99)
–c –c
–c –c
33 to 97e 56 to 98e
42 (15 to 72)d 93 (81 to 99)d
s; mixed)b 74 (51 to 88) 75 (45 to 91)
ions; mixed)b 80 (53 to 93) 87 (54 to 97)
–c –c
–c –c
86 (82 to 89) –c
–c 86 (77 to 92)
0 to 100e 18 to 100e
17 to 85e 74 to 96e
d scans; mixed)b 83 (81 to 84) 85 (83 to 87)
d scans; mixed)b 78 (70 to 84) 88 (82 to 92)
ith 95% confidence interval (CI), except for: Xing and colleagues, specification
mean values with CI; our review, specification of ranges. bThe results of these
uantitative synthesis was not possible due to heterogeneity. dData based on
f the results was not possible. Therefore a range of data is provided. Data of
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Guyatt tool, we have some doubts about the validity of
the analysis performed by Xing and colleagues.
Assessment of risk of bias in primary studies
Different reference standards will be employed in
patients with positive and negative PET scan results.
Most metastases will be confirmed histologically, while
apparently disease-free patients will remain under regu-
lar clinical observation. This issue should be listed as a
possible source of differential verification bias (item 5)
for all studies; the item’s possible impact is then a matter
of judgment – scoring this item negatively does not ne-
cessarily mean that the whole study was biased. We
judged that histology results and follow-up results will
often have similarly high validity, so that this item was
essentially not used to decide about the validity of
included studies.
Limitations
One of the major limitations of this systematic review is
the low quality of reporting in the studies considered.
Studies were often described inadequately. In some stud-
ies it was not possible to determine whether they had a
retrospective or a prospective design. Furthermore, in
some cases it was not clear which cutoff values were
used and when the index test PET(/CT) or the reference
test was applied.
We performed a review of reviews. Results of risk-of
bias assessment were therefore taken from included
reviews. A comparison of the results of the risk-of-bias
assessment was hampered by the fact that different as-
sessment tools were used and by inadequacies such as a
lack of distinction between internal and external validity
or a lack of categorization of studies into those with a
high or a low risk of bias. In accordance with the
authors of the reviews, we also concluded that many
studies failed to provide sufficient details to adequately
assess risk-of-bias items.
Conclusions
There is currently no evidence for a patient-relevant
benefit of PET(/CT) in primary staging of malignant
melanoma, indicating that it may be too early for broad
clinical use of this technology. In future, stage-adapted
RCTs investigating patient-relevant outcomes are needed
to determine whether PET(/CT) actually has a benefit
for patients.
The diagnostic accuracy of PET(/CT) appears to in-
crease with higher AJCC stages. However, regardless of
the indication (N-staging or M-staging), the ranges for
sensitivity and specificity were wide. In addition, the 17
studies on diagnostic accuracy were heterogeneous,
some were small and many showed methodologicaldeficiencies. Future diagnostic accuracy studies should
be prospective, of better quality, and better reported.
Additional file
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